Number of shares and votes in BioArctic AB (publ) as of February 27, 2026

Rhea-AI Summary

BioArctic (Nasdaq Stockholm: B) issued 78,000 Class B shares in February 2026 under the 2019/2028 stock option program. As of February 27, 2026 the company had 88,719,485 shares: 74,319,489 listed Class B and 14,399,996 unlisted Class A. A shares carry ten votes; B shares carry one vote, giving a total of 218,319,449 votes.

Contact details for investor relations are provided for further inquiries.

News Market Reaction – BIOA

-0.22%

1 alert

-0.22% Session close to close

$931.92M Market Cap

2.60K Volume

In the Feb 27 session, BIOA declined 0.22%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, Feb. 27, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 78,000 Class B shares during February for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 78,000 stock options of series 2019/2028.

As of February 27, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,719,485 shares, of which 74,319,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per share and the B share has one vote per share. The total number of votes in the company amounts to 218,319,449.

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on February 27, 2026, at 18.30 CET.

For more information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com 
Tel: +46 704 10 71 80

Anders Martin-Löf, CFO
E-mail: anders.martin-lof@bioarctic.com 
Telephone +46 70-683 79 77
 

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson-related diseases and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/number-of-shares-and-votes-in-bioarctic-ab--publ--as-of-february-27--2026,c4314113

The following files are available for download:

https://mb.cision.com/Main/9978/4314113/3956238.pdf

Number of shares and votes in BioArctic AB (publ) as of February 27, 2026

View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-bioarctic-ab-publ-as-of-february-27-2026-302699840.html

SOURCE BioArctic

FAQ

How many shares did BioArctic (B) issue in February 2026 under the 2019/2028 option program?

BioArctic issued 78,000 Class B shares in February 2026. According to BioArctic, these shares were delivered via exercise of 78,000 stock options from the 2019/2028 series resolved at the Annual General Meeting on May 9, 2019.

What is the total number of outstanding shares in BioArctic (B) as of February 27, 2026?

As of February 27, 2026, BioArctic had 88,719,485 shares outstanding. According to BioArctic, that total comprises 74,319,489 listed Class B shares and 14,399,996 unlisted Class A shares.

How many votes does each class of BioArctic (B) share carry as of Feb 27, 2026?

Class A shares carry 10 votes each and Class B shares carry 1 vote. According to BioArctic, this voting structure results in a combined total of 218,319,449 votes as of February 27, 2026.

What is the effect on total votes after BioArctic (B) issued 78,000 Class B shares in February 2026?

Issuing 78,000 Class B shares increased the share count but had a limited vote impact. According to BioArctic, total votes stand at 218,319,449 as of February 27, 2026, reflecting the existing A/B voting ratio.

Were the February 2026 share issues in BioArctic (B) part of an approved shareholder program?

Yes, the February 2026 share issuance followed the 2019/2028 stock option program approved at the AGM on May 9, 2019. According to BioArctic, shares were issued through exercise of options from that authorized series.

Where can investors get more information about BioArctic's share count update on Feb 27, 2026?

Investors can contact BioArctic's investor relations for details. According to BioArctic, contact persons listed include Oskar Bosson (VP Communications and IR) and Anders Martin-Löf (CFO) with provided email addresses and telephone numbers.